Alana R. Amarosa1, Hersh Chandarana1, Stella K. Kang1, Mary T. Bruno1, Konstantinos Arhakis1, William C. Huang2, Edgar F. Suan1, Sungheon Kim1
1Radiology, NYU School of Medicine, New York, United States; 2Urology, NYU School of Medicine, New York, United States
The purpose of this study was to investigate the feasibility of dynamic contrast enhanced perfusion MRI with pharmacokinetic modeling to generate and analyze parameters, ktrans, ve, vp, for discrimination of renal cell cancer (RCC) subtypes. In this prospective study 22 patients with known or suspected renal tumors underwent preoperative DCE-MRI at 1.5T. The generalized kinetic model was used for pharmacokinetic analysis to obtain ktrans, ve, vp for total of 23 lesion. Significant differences were found in ktrans between clear cell RCC and oncocytic tumors (p = 0.038) and between clear cell and papillary RCCs (p = 0.074).